Howell K, Costello CM, Sands M, Dooley I, McLoughlin P. L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 296: L1042-L1050, 2009. First published April 3, 2009 doi:10.1152/ajplung.90327.2008.-Chronic alveolar hypoxia, whether due to residence at high altitude or lung disease, leads to a sustained increase in pulmonary vascular resistance and pulmonary hypertension (PH). Strategies that augment endogenous nitric oxide production or activity, including L-arginine supplementation, attenuate the development of PH. This action has been attributed to inhibition of vessel wall remodeling, thus preventing structural narrowing of the vascular lumen. However, more recent evidence suggests that structural changes are not responsible for the elevated vascular resistance observed in chronic hypoxic PH, calling into question the previous explanation for the action of L-arginine. We examined the effect of dietary L-arginine supplementation on pulmonary vasoconstriction, structurally determined maximum vascular lumen diameter, and vessel length in rats during 2 wk of exposure to hypoxia. L-Arginine attenuated the development of hypoxic PH by preventing increased arteriolar resistance. It did not alter mean maximal vascular lumen diameter, nor did it augment nitric oxidemediated vasodilatation, in chronically hypoxic lungs. However, the total length of vessels within the gas exchange region of the hypoxic lungs was significantly increased after L-arginine supplementation. These findings suggest that dietary L-arginine ameliorated hypoxic PH, but not by an effect on the structurally determined lumen diameter of pulmonary blood vessels. L-Arginine enhanced angiogenesis in the hypoxic pulmonary circulation, which may attenuate hypoxic PH by producing new parallel vascular pathways through the lung. vascular endothelial growth factor; nitric oxide; hypoxia; lung disease CHRONIC ALVEOLAR HYPOXIA, whether due to residence at high altitude or lung disease, leads to a sustained increase in pulmonary vascular resistance and pulmonary hypertension (PH). When such secondary hypertension occurs in the setting of chronic lung diseases, such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease, it is associated with increased morbidity and reduced survival (29, 36) .
CHRONIC ALVEOLAR HYPOXIA, whether due to residence at high altitude or lung disease, leads to a sustained increase in pulmonary vascular resistance and pulmonary hypertension (PH). When such secondary hypertension occurs in the setting of chronic lung diseases, such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease, it is associated with increased morbidity and reduced survival (29, 36) .
Nitric oxide (NO) produced by the pulmonary endothelium is an important modulator of the pulmonary vascular responses to acute and chronic hypoxia (25) . In normal and chronically hypoxic lungs, endogenous NO production reduces basal pulmonary vascular resistance and attenuates the acute hypoxic vasonconstrictor response (11, 24, 53) . Chronic hypoxia impairs endothelium-dependent relaxation in pulmonary vessels (1, 15, 53) and reduces NO production compared with normoxic conditions (44, 45) . Further reduction of NO production by targeted endothelial NO synthase (NOS) gene deletion in mice significantly worsens PH and increases vascular remodeling (16, 31, 70) . Conversely, strategies that augment endogenous NO production or activity, including L-arginine supplementation (13, 18, 38, 41, 45, 51) , statins (21, 22, 47, 73) , and sildenafil (20, 62, 66, 73) , attenuate the development of PH. Inhaled NO has also been shown to successfully reduce PH in humans (10, 15) and in rodent models of hypoxia-induced PH (34, 64, 65) .
The ability of NO to alleviate hypoxic PH has been attributed predominantly to its inhibition of the remodeling of the walls of pulmonary resistance vessels, thus preventing encroachment into the lumen and the resultant structural narrowing (34, 45) . However, Laursen et al. (35) recently demonstrated that augmented NO production did not prevent hypoxiainduced vascular remodeling. Furthermore, recent evidence suggests that structural changes are not responsible for the elevated vascular resistance observed in chronic hypoxic PH in rodents (32, 49, 50, 52) . In support of this evidence, our group reported that hypoxia-induced vascular wall remodeling occurs in an outward direction and does not reduce the lumen diameter (30, 32) . It has also been reported that hypoxic PH is predominantly due to Rho kinase-mediated vasoconstriction (17, 32, 49) . These findings cast doubt on the hypothesis that increased NO acts to alleviate hypoxic PH by preventing vascular wall remodeling (wall thickening) that encroaches into the lumen.
We considered alternative potential explanations for the antihypertensive effect of NO. One possible mechanism was that endogenous NO acted through its well-known vasodilator activity. We also considered a further possible mechanism of action: in the systemic circulation, NO has proangiogenic activity. Many proangiogenic growth factors stimulate increased NO production, which is required for normal systemic angiogenesis in the adult animal (3, 4, 7, 19, 48, 55, 63, 76, 77) . We recently showed that chronic hypoxia causes angiogenesis in the adult rat pulmonary circulation (30, 32) . Taken together, these reports suggest that augmentation of endogenous NO production could stimulate new vessel growth, thus increasing total vessel length in the chronically hypoxic lung. If new vessels developed so that additional parallel pathways were formed through the pulmonary circulation, pulmonary vascular resistance would be reduced.
The aim of the present study was to examine the effects of dietary L-arginine supplementation, at a dose known to alleviate hypoxic and monocrotaline-induced PH (45, 51, 68) , on pulmonary vasoconstriction, structurally determined maximum vascular lumen diameter, and the length of vessels in chronically hypoxic rats.
METHODS
All procedures were approved by the University Ethics Committee and conducted under license from the Department of Health. Adult male Wistar Kyoto specific-pathogen-free rats (300 -350 g body wt; Harlan, Bicester, UK) were used in all experimental protocols. All animals were exposed to the same 12:12-h light-dark cycle, and food and water were provided ad libitum. Rats were randomly assigned to one of three experimental conditions. Chronically hypoxic rats were housed in a normobaric hypoxia chamber (10% O 2) for 2 wk with free access to food and water as previously described, a condition that leads to the development of hypoxic PH (30, 53) . This 2-wk study period was chosen because of previous demonstrations that hypoxiainduced vascular wall remodeling in the rat lung stabilized after 14 days of hypoxia and the increased pulmonary vascular resistance was "fixed," i.e., unchanged by abrupt restoration of normal O2 and unresponsive to conventional vasodilators (26, 27, 43, 61) . All rats were housed in individual cages, so that food and water intake could be monitored. Further groups of rats were housed in identical hypoxic conditions for 2 wk, but, in addition, their drinking water contained L-arginine (95 mM). On the basis of measured water intake, the increment in L-arginine intake was 530 -650 mg/day, a dose that has been shown to inhibit the development of PH in rats (45, 51, 68) . In non-L-arginine-supplemented control and hypoxic groups, dietary L-arginine intake was 100 -200 mg/day.
Control rats were housed in room air (21% O2) immediately adjacent to the hypoxia chamber. Concentrations of gas in the chamber were controlled using an automated computer-based O2 and CO2 control system [ProOx model 110 (O 2 controller) and ProCO2 (CO2 controller), Biospherix]. CO2 was removed by continuous recirculation of gases from the chamber through soda lime. Excess humidity and ammonia were removed using a cooled condensing unit and an activated charcoal filter (Carbon-Cap 150, Whatman, Maidstone, UK), respectively. Exposure to the chamber environment was continuous, except for a brief period each day when the chamber was opened, while the cages were cleaned and food and water were replenished.
Hemodynamic responses. Pulmonary hemodynamic responses to the experimental conditions were assessed using an isolated ventilated perfused lung preparation, as previously described (32) . Control (n ϭ 7), hypoxic (n ϭ 8), and hypoxic-L-arginine (n ϭ 9) rats were anesthetized with pentobarbital sodium (60 mg/kg ip) and mechanically ventilated with a small-animal ventilator (model SAR-830P, CWE, Ardmore, PA) at a tidal volume of 1.8 ml and a respiratory frequency of 80 breaths/min. Heparin was administered (1,000 IU/kg iv), and the rats were killed by exsanguination; a blood sample was obtained for determination of hematocrit. The thoracic contents were exposed through a midline sternotomy, and the main pulmonary artery and left atrium were cannulated. The heart and lungs were removed en bloc, suspended in a warmed (37°C), humidified chamber, and ventilated. Normoxic rats were ventilated with a normoxic gas mixture of 5% CO2-21% O2-balance N2, and hypoxic rats were ventilated with a hypoxic gas mixture of 5% CO2-7% O2-balance N2.
Arterial, venous, and airway pressures were continuously recorded with an analog-to-digital system (Biopac MP100 WS, Linton Instrumentation, Norfolk, UK). A positive end-expiratory pressure of 2 cmH2O was maintained, and the lungs were hyperinflated to an airway pressure of 16 cmH2O every 5 min to prevent the development of progressive atelectasis. Lungs from all groups were perfused with an identical mixture of 20 ml of normoxic blood obtained from donor rats maintained in normal O2 and 10 ml of physiological saline solution (121 mM NaCl, 21 mM NaHCO3, 5.4 mM KCl, 4 mM MgSO4, 1 mM NaH2PO4, 1.8 mM CaCl2, 5.6 mM d-glucose, and 4% Ficoll). The concentration of L-arginine in normal rat plasma is ϳ160 M (58) . Thus the concentration of L-arginine in the perfusate exceeded 100 M, a concentration sufficient to support maximal endothelial NO production and maximum endothelium-dependent relaxation (58).
Perfusion was initially maintained at a constant flow (0.04 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ), so that changes in arterial perfusion pressure reflected changes in total pulmonary vascular resistance. Venous outflow pressure was maintained constant at 3.5 mmHg (4.8 cmH 2O) to ensure zone 3 conditions at the end of expiration [pulmonary arterial pressure (PAP) Ͼ pulmonary venous pressure Ͼ pulmonary alveolar pressure]. All measurements of arterial perfusion pressure were made at end of expiration. PAP was measured at two further steady flow rates (0.06 and 0.08 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ). At baseline (flow rate ϭ 0.04 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ), capillary pressure (P c) was assessed by the double-occlusion technique (32) . Briefly, inflow and venous outflow lines were simultaneously occluded, so that the vascular pressure rapidly equilibrated to a new pressure representative of P c. This allowed pre-and postcapillary resistances to be calculated separately. N-nitro-L-arginine methyl ester (L-NAME, 10 Ϫ4 M), a nonspecific NOS inhibitor, was subsequently added to the reservoir to assess the contribution of NO production to vascular tone, and P c was once again measured. At the end of each experiment, the lungs were snap frozen and stored for subsequent mRNA analysis.
Assessment of pulmonary vascular structure. Control (n ϭ 6), hypoxic (n ϭ 8), and hypoxic-L-arginine (n ϭ 6) rats were anesthetized with pentobarbital sodium (60 mg/kg ip), anticoagulated with heparin (1,000 IU/kg iv), and exsanguinated via the femoral artery; a sample of blood was obtained for determination of hematocrit. The heart and lungs were removed en bloc after cannulation of the trachea, left atrium, and pulmonary artery. Normal saline was infused through the pulmonary circulation until the effluent ran clear. The lungs were then inflated via the trachea with fixative (4% paraformaldehyde) at a pressure of 25 cmH2O. The pulmonary arterial perfusion pressure was elevated to 67.5 cmH2O after the left atrial outflow had been clamped (30) . This "no-flow" perfusion system produced a constant, transmural distending pressure (37.5 cmH2O) at all locations along the vascular bed. After 20 min, the main stem bronchi and pulmonary artery were tied off at the hilum, the lungs were stored in fixative (4% paraformaldehyde) for 24 h, and the lung volumes were determined by water displacement (69) . After removal of the atria, the right ventricular (RV) free wall was dissected from the left ventricle ϩ septum, and each ventricle was weighed separately.
The left lung (single lobe) was processed for stereological quantification of the pulmonary vascular bed as previously described (30) . Briefly, the lung was divided into multiple blocks selected by a systematic randomized strategy, each block having a vertical uniform random face. A cosine weighted orientator clock was used to identify isotropic uniform random planes on the vertical uniform random faces, and sections (1 m) were cut from the resin-embedded tissue and stained with toluidine blue (30) .
Random microscopic images of the lung sections were selected (ϫ20 objective, Olympus BX61 motorized microscope) using a semiautomated computer-assisted stereological toolbox (CAST) system (Visiopharm integrator system version 2.9.11.0, Olympus Denmark). The images were digitized (Olympus DP70 digital camera) and displayed on a screen with superimposition of a stereological grid ( Fig. 1) , which allowed determination of the length density of the vessels within the gas exchange region of the lung (intra-acinar vessels) and unbiased selection of vessels for direct measurement of lumen diameter. With use of this strategy, the probability of selection of a vessel for lumen diameter determination was directly proportional to its length (6, 28) . The lumen diameter was taken as the maximum distance across the lumen measured perpendicular to a line drawn along the longest axis of the image of the transected lumen (Fig. 1) . The external diameter was measured at the same position as the lumen diameter. Wall thickness was calculated as one-half of (external diameter Ϫ lumen diameter) and expressed as the ratio of wall thickness (intima, media, and adventitia) to external diameter for vessels with lumen diameters of 10 -100 m (see Fig. 6 ).
A point-counting grid that allowed determination of the volume fraction of the vascular lumen within the lung was also included.
Intra-acinar vessels were identified as those accompanying respiratory bronchioles or more distal airways and alveoli with lumen diameter Ͼ10 m and Ͻ100 m. All slides were identified by code, so that the observer was blinded to the experimental conditions in which the rats had been housed.
Data analysis. Total vessel length within each left lung was calculated by multiplication of the length density by the lung volume. Vessels were divided into categories on the basis of their lumen diameters (10-m intervals), and the number in each category was recorded. The average vascular lumen diameter in each lung was calculated as the sum of all measured diameters divided by the total number of measurements made in that lung. Inasmuch as vessels of different lumen sizes were sampled in proportion to the total length of vessels of that size in the lung, the resultant average diameter was weighted in proportion to the length of vessel in each category. The relative frequencies with which vessels in each category occurred were calculated. Multiplication of the relative frequency by the total length of intra-acinar vessels yielded the length of vessel within each category in that lung.
To confirm the validity of the data obtained using this approach, we undertook a preliminary study of lungs from a separate group of rats (n ϭ 19) in which the lungs were isolated, fixed, and sectioned and random microscopic images were obtained as described above. The total volume of the vascular lumen contained within these lungs was calculated by two separate methods. 1) Lumen volume was determined in each lung by calculation of the volume fraction of vessel lumen within the lung by the standard point-counting technique ( Fig.  1) and multiplication of that value by the volume of the lung (6, 28) .
2) The lumen volume of the vessels within each diameter category in a lung was calculated using the standard formula, r 2 l, where r is the radius of vessels in that category and l is the total length of vessel in the category. Total lumen volume was then calculated as the sum of the volumes of vessels in all the categories in that lung. Thus two values for the lumen volume were obtained independently in each lung. The values (mean Ϯ SD) for lumen volume calculated on the basis of vessel length and diameter (0.057 Ϯ 0.010 cm 3 ) and point counting (0.059 Ϯ 0.012 cm 3 ) were not significantly different. These results demonstrate the validity of the estimates of vessel length within categories.
Extraction and real-time PCR quantification of mRNA. Snap-frozen lung tissue samples were crushed to a fine powder under liquid nitrogen (mortar and pestle) and dissolved in RNeasy lysis buffer (Qiagen) with vigorous vortexing. After thorough homogenization (30-s bursts for 5 min) with a homogenizer (Polytron PT1200CL, Kinematica), samples were further shredded on QIA shredder columns (Qiagen). Total RNA was extracted and treated with DNase using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol, with the exception that DNase treatment was carried out twice for 30 min. RNA was eluted in RNase-free water and assessed by standard formaldehyde gel electrophoresis. RNA concentration was measured spectrophotometrically at 260 nm. Total RNA (1 g) was reverse transcribed to cDNA using the SuperScript II RNase H-reverse transcriptase kit (Invitrogen) according to the manufacturer's instructions.
The mRNA of genes of interest was quantified using real-time PCR (TaqMan) performed on duplicate samples on 384-well plates. An initial PCR without a reverse transcriptase step confirmed that all RNA samples were free of contaminating genomic DNA. Probe [labeled with 5(6)-carboxyfluorescein (FAM)/6-carboxytetramethylrhodamine (TAMRA)] and primer sequences were ordered from Applied Biosystems (ABI) as Assays-on-Demand Gene Expression Assays ( Table 1 ). The eukaryotic 18S rRNA (VIC/TAMRA) predeveloped assay reagent kit was used as the endogenous control gene according to the TaqMan PCR protocol (ABI). Reactions were carried out on the Prism 7900 Sequence Detection System (ABI), and mRNA levels were determined using the standard curve method (Prism 7700 Sequence Detection System User Bulletin #2, ABI).
Statistical tests. Values are group means Ϯ SE; n refers to the number of rats from which tissue was obtained. For multiple comparisons of means across experimental groups, ANOVA was performed followed by Student-Newman-Keuls post hoc test for pair-wise comparisons. Where appropriate, repeated-measures ANOVA was used. P Ͼ 0.05 was accepted as statistically significant.
RESULTS
Dietary supplementation with L-arginine did not affect the body weight or the elevation in hematocrit caused by hypoxia, although hypoxia-induced RV hypertrophy was significantly attenuated (Table 2) . Chronic hypoxia produced an increase in left lung volume compared with control lungs, an increase that was unaffected by dietary L-arginine (Table 2) .
Hemodynamic changes. As expected, chronic hypoxia significantly augmented baseline PAP compared with control conditions (Fig. 2) by increasing precapillary resistance (Fig. 3) . In chronically hypoxic lungs, dietary L-arginine maintained PAP close to control values (Fig. 2) by abrogating the increase in precapillary resistance (Fig. 3) . Postcapillary resistance was not significantly altered in either of the experimental conditions (Fig. 3) .
The role of ongoing endogenous NO production in modulating vascular resistance was investigated by addition of the NOS inhibitor L-NAME to the perfusate in all three groups of isolated lungs. Although addition of L-NAME resulted in a significant increase in resistance in all three conditions compared with the values observed before NOS inhibition, resistance remained significantly lower in the hypoxic-L-arginine group than in the hypoxic group and was similar to resistance in the control group (Fig. 4) , suggesting that an acute vasodilator activity of NO was not responsible for preventing the development of PH. Pulmonary vascular structure. Characteristically remodeled intra-acinar vessels were seen in the lungs exposed to chronic hypoxia compared with control lungs (Fig. 5) . However, mean measured lumen diameter was not significantly altered in either hypoxic group compared with the control group ( Table 3) . The mean ratio of wall thickness to external diameter was significantly augmented in the hypoxic lungs (Fig. 6) , consistent with the development of hypoxia-induced vascular remodeling; Larginine did not alter this hypertrophic response (Fig. 6) . The intra-acinar vessel length per unit volume of lung (vessel length density) was similar in control and hypoxic lungs; however, the presence of L-arginine significantly augmented vessel length density (data not shown). Total vessel length was significantly augmented in chronically hypoxic lungs compared with controls, and L-arginine supplementation during hypoxic exposure further augmented this response (Table 3) . This increase in length occurred largely through an increase in the length of the vessels of smallest diameter (Fig. 7) .
Vascular growth factors.
We examined expression of proangiogenic growth factors from the VEGF family and found that, after 2 wk of hypoxia, only placental growth factor was significantly elevated, whereas VEGF-A, -B, and -C were not significantly altered (Fig. 8) . Interestingly, in the L-argininesupplemented group, VEGF-C was elevated above the level in control and the non-L-arginine-supplemented-hypoxic group. In contrast, hypoxia led to a reduced expression of VEGF receptors 1 and 2, and this expression was unaltered by dietary L-arginine (Fig. 8) .
DISCUSSION
Previous studies have shown that L-arginine supplementation increased NO production and alleviated PH (15, 18, 23, 41, 45) . The aim of the present study was to examine the mechanisms by which such L-arginine supplementation might attenuate chronic hypoxic PH.
In the present study, the chronically hypoxic rats showed the well-documented consequences of hypoxic exposure, including increased pulmonary vascular resistance (Fig. 2) , aug- Fig. 2 . Pulmonary arterial pressure (PAP) in isolated ventilated perfused lungs of control rats (n ϭ 7), hypoxic rats (n ϭ 8), and hypoxic-L-argininesupplemented (hypoxic-L-arginine) rats (n ϭ 9) at flow rates of 0.04, 0.06, and 0.08 ml ⅐ min Ϫ1 ⅐ kg
Ϫ1
. Values are means Ϯ SE. *Significantly different from hypoxic (P Ͻ 0.05, by ANOVA). †Significantly different from control (P Ͻ 0.05, by ANOVA). . PAP in isolated ventilated perfused lungs of control (n ϭ 7), hypoxic (n ϭ 8), and hypoxic-L-arginine (n ϭ 9) rats at a flow rate of 0.04 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 under basal conditions and after nitric oxide synthase inhibition with nitro-L-arginine methyl ester (L-NAME). Pre-L-NAME values are those shown in Fig. 2 at the same flow rate and are reproduced here to facilitate comparison with post-L-NAME values. Values are means Ϯ SE. *Significantly different from hypoxic (P Ͻ 0.05, by ANOVA). †Significantly different from control (P Ͻ 0.05, by ANOVA).
§ Significantly different from pre-L-NAME. mented wall thickness (Fig. 6) , RV hypertrophy, elevated hematocrit (Table 2) , and increased lung volumes (Table 2) , as previously reported (12, 30, 32, 33, 41, 45, 49, 56, 61) . In addition, we observed increased total length of the pulmonary vessels, suggesting angiogenesis, a finding supported by recent reports (5, 30, 32, 57) , although others have reported loss of pulmonary vessels in this condition, as recently reviewed (39, 40, 60) .
We found that L-arginine treatment ameliorated the hypoxiainduced PH (Figs. 2 and 3) , largely by preventing hypoxiainduced increases in resistance in the arteriolar (precapillary) vessels (Fig. 3) . This antihypertensive effect was not mediated by a general inhibition of hypoxic responses, since other effects of hypoxia, including increased hematocrit and lung volume, were unaltered.
We considered the potential mechanisms by which L-arginine supplementation might have attenuated the development of PH. First, it could have acted by enhancing vasodilatation due to endogenously produced NO. However, if this had been the case, then NOS inhibition would have caused resistance in the hypoxic-L-arginine group to rise to a level similar to that of the hypoxic lungs. In contrast, after NOS inhibition, PAP in the isolated ventilated L-arginine-supplemented lungs was similar to that in the control group and significantly less than that in the hypoxic group (Fig. 4) . In fact, the difference between the L-arginine-supplemented group and the hypoxic group after NOS inhibition was as great as that before inhibition (Figs. 2  and 4 ). These findings demonstrate that L-arginine was not acting to reduce pulmonary vascular resistance by augmenting the vasodilator action of endogenous NO production.
We next considered the possibility that L-arginine supplementation acted to attenuate hypoxic PH by preventing structural narrowing of the lumen of the pulmonary vessels. However, we could find no evidence of this, inasmuch as the mean lumen diameter in the hypoxic-L-arginine group was not significantly different from that in the hypoxic group (Table 3) . Furthermore, the mean diameter in the untreated hypoxic group was not reduced below the value in control lungs (Table 3) . This is in good agreement with our previous findings, although the method we used to determine mean lumen diameter was different from the method we used previously (30, 32) . In those previous studies, we calculated mean lumen diameter from the total lumen volume and total length of the maximally dilated vessels; in the present study, we directly measured lumen diameter. In addition, this study shows that vascular wall Values are means Ϯ SE. *Significantly different from hypoxic; †signifi-cantly different from control (P Ͻ 0.05, by ANOVA). remodeling, characteristic of chronically hypoxic lungs, was not affected by the presence of L-arginine (Fig. 6 ). This finding is in agreement with a recent report that long-term oral Larginine administration did not prevent the development of vascular media hypertrophy in chronically hypoxic rats (35) . Taken together, these findings are in good agreement with recent evidence that chronic hypoxic PH results predominantly from sustained Rho kinase-mediated vascular smooth muscle contraction and is not the result of structural narrowing of the vascular lumen (17, 32, 49) .
Since we could not find evidence that L-arginine reduced hypoxia-induced PH by vasodilatation or by prevention of vascular wall thickening or encroachment into the lumen caused by hypertrophy, we considered an alternative explanation. We previously showed that chronic hypoxia causes angiogenesis in the adult rat pulmonary circulation (30, 32) , and the data presented here support this finding. Importantly, Meyrick and Reid (42) demonstrated that sustained hypoxia leads to uptake of radiolabeled thymidine by the endothelial cells of the extra-and intra-acinar vessels, demonstrating proliferation within these cells, a finding compatible with angiogenesis. Here, we show, for the first time, that L-arginine augments this angiogenic response, leading to a further increase in intrapulmonary vessel length (Table 3 , Fig. 7 ). This angiogenic action of L-arginine supplementation is consistent with previous evidence of such an effect in the systemic circulation (3, 4, 7, 19, 48, 55, 63, 76, 77) . The increase in length was accompanied by a reduction of resistance in the arteriolar segment of the pulmonary circulation (Fig. 3) . Given that the vascular lumen diameter was unchanged, angiogenesis caused solely by elongation would have increased resistance. In contrast, if new vessels had grown by branching and the formation of new parallel pathways through the lung, resistance would have been reduced. Our findings are compatible with the latter explanation and suggest a novel mechanism by which L-arginine might act to ameliorate PH.
It is important to highlight a number of key differences between the present study and other studies that have examined this issue. Previous studies used casting techniques that permit identification of pulmonary arterioles and focused on that segment of the circulation (26, 27, 43, 61) . Our method of fixation ensured that all vessels were fixed at standard transmural pressures and, therefore, permitted clear conclusions about the dimensions of the vascular lumen, as previously discussed (30, 39, 40) . However, we cannot discriminate between arterial and venous vessels. Therefore, we cannot assume that vessel length increased in all segments. Indeed, our data are potentially compatible with loss of vessels in one (e.g., the arterial) segment and simultaneous angiogenesis in another (e.g., the venous) segment (30) . A second important methodological difference from previous studies is that we used semithin resin sections, which give the highest-quality morphology by light microscopy, and did not use endothelial cell markers to examine angiogenesis. We chose this approach, because endothelial cell markers are not uniformly expressed throughout the pulmonary vasculature. For example, von Willebrand factor is highly expressed in larger pulmonary vessels but is not expressed or only weakly expressed in the smaller intra-acinar vessels (unpublished data), a finding that has recently been reported by others (59) . Furthermore, markers that were first thought to be endothelial cell specific (including platelet endothelial cell adhesion molecule and VEGF receptor 2) are expressed on many other cells, including platelets, monocytes, macrophages, neutrophils, and epithelial and neural cells (2, 14, 37, 54, 75) . All these cells are abundant throughout the lung and can change in response to hypoxia. Another problem is that the expression of endothelial cell markers on cells is altered by hypoxia and, moreover, can change in opposite ways in vessels of different sizes within the same vascular bed (2, 8, 46) . For these reasons, changes in the expression of endothelial cell markers do not directly reflect angiogenesis.
A further aspect of our study design is that we used in-bred Wistar Kyoto rats, whereas some other groups used SpragueDawley rats (45) . Strain differences in response to hypoxia are well documented and could certainly contribute to differences in results. Indeed, within species and strains, it is well established that there are very marked interindividual responses to hypoxia. The effects of these differences in hypoxic responses between strains and individuals within strains require further Fig. 7 . Length of intra-acinar vessels categorized according to lumen diameter in left lungs from control (n ϭ 6), hypoxic (n ϭ 8), and hypoxic-L-arginine (n ϭ 6) rats. Values are means Ϯ SE. ‡Significantly different from all other groups (P Ͻ 0.05, by repeated-measures ANOVA). Hypoxia-induced angiogenesis, indicated by a significant increase in the length of small vessels (10 -20 m) , is further augmented in the hypoxic-L-arginine group. Fig. 8 . Growth factor and associated receptor mRNA (determined by quantitative real-time PCR) normalized to mean values under control conditions for control (n ϭ 6), hypoxic (n ϭ 6), and hypoxic-L-arginine (n ϭ 6) lungs. VEGFR-1 and VEGFR-2, VEGF receptor 1 and 2, respectively; PlGF, placental growth factor. *Significantly different from hypoxic (P Ͻ 0.05, by ANOVA). †Significantly different from control (P Ͻ 0.05, by ANOVA).
investigation. Finally, more prolonged periods of hypoxic exposure could produce changes beyond the 2-wk period of our study.
To gain insight into the growth factors that maintained the L-arginine-induced angiogenesis, we examined the expression of growth factors from the VEGF family, which are known to play an important role in angiogenesis in the systemic circulation (71) . In the hypoxic group, only placental growth factor was elevated above control values, whereas in the hypoxic-Larginine group, VEGF-C was also significantly elevated (Fig.  8) . In addition to its well-known lymphangiogenic action, VEGF-C has potent proangiogenic activity in the systemic circulation (9, 67, 72, 74) . Taken together with the findings that we report here, this suggests that dietary supplementation with L-arginine may have acted, at least in part, by increasing the proangiogenic action of this growth factor. Further work is needed to investigate more completely this possibility.
In summary, we have demonstrated that L-arginine alleviates chronic hypoxic PH in vivo but did not produce this effect by preventing structural narrowing of the vascular lumen. Our data suggest that L-arginine supplementation promoted angiogenesis in the chronically hypoxic lung, resulting in an increase in the number of parallel vascular pathways through the pulmonary circulation and reduced vascular resistance. This represents a previously unsuspected mechanism that can ameliorate PH, which should be considered in an investigation of therapeutic interventions for the treatment of this condition. 
